You get it, you manage it. You don’t get rid of it. Every appointment reinforced the framing — medications adjusted, target numbers chased, nobody ever once suggesting the condition itself might be reversible.
He read about the DiRECT trial online at 11 PM on a Tuesday. A UK study: half the participants with type 2 diabetes randomized to intensive dietary intervention, the other half to standard care. At twelve months, 46% of the intervention group had achieved remission — A1c below 6.5%, no diabetes medications. He read the figure three times. Not improvement. Not better management. Remission.
He called his doctor the next morning.
Type 2 diabetes reversal — remission, to use the more precise term — has gone from fringe claim to mainstream clinical reality in about a decade. The evidence base is substantial now: multiple large randomized trials, mechanistic studies explaining exactly why and how it works, expert consensus statements from the major diabetes organizations acknowledging remission as a legitimate, achievable goal. The science is settled. Clinical practice is still catching up.
This is the comprehensive evidence-based guide to what type 2 diabetes reversal actually is, what the science says, how it works biologically, and what the realistic paths to achieving it look like.
DEFINING REMISSION: WHAT REVERSAL ACTUALLY MEANS
“Reversal” needs precision before it’s useful for anything. An expert consensus statement from the American Diabetes Association, Endocrine Society, European Association for the Study of Diabetes, and Diabetes UK — published in Diabetes Care, 2021 — established formal definitions:
Remission means A1c below 6.5% for at least three months, no glucose-lowering medications. Subcategories: partial remission (A1c 6.0-6.5%), complete remission (below 6.0%), prolonged remission (complete remission sustained 5+ years). The consensus statement is explicit that remission is a return to normal or near-normal glucose metabolism, not a cure — the underlying metabolic vulnerability is still there, and remission needs sustained lifestyle maintenance to hold.
Worth sitting with that distinction. Remission isn’t cure. It’s normal glucose homeostasis achieved by clearing out enough of the driving factors — mainly visceral and ectopic fat sitting in the liver and pancreas — to let beta cell function come back online. Let those factors return (weight regain, going sedentary, sliding back to high-glycemic eating) and glucose climbs again. Maintenance isn’t optional.
Who gets there? The evidence points to: shorter diabetes duration (under 6 years), higher starting A1c (more room to move), bigger initial weight loss, no insulin dependence (meaning some beta cell function survives), younger age at onset. DiRECT found 46% of participants — mean duration 2.9 years — achieved remission at 12 months; at 24 months, 36% still had it.
DIRECT-Plus, run in Israel with a Mediterranean approach, hit 61% remission at 18 months in a comparable group.
THE TWIN CYCLE HYPOTHESIS: WHY DIABETES REVERSES WITH WEIGHT LOSS
Professor Roy Taylor at Newcastle University has spent two decades building and testing the Twin Cycle Hypothesis — now the most compelling mechanistic account of why type 2 diabetes develops and why it reverses with weight loss. Understanding it flips the clinical story from “managing a chronic progressive disease” to “removing the cause of a reversible metabolic dysfunction.”
Two linked vicious cycles. Cycle 1: when caloric surplus chronically outpaces the liver’s fat-oxidizing capacity, triglycerides pile up in hepatic tissue — non-alcoholic fatty liver disease. Hepatic fat drives hepatic insulin resistance: the liver keeps producing glucose even when insulin is telling it to stop, which is the fasting hyperglycemia that defines type 2 diabetes.
Compensatory hyperinsulinemia from the pancreas patches this over at first, but the excess insulin drives more hepatic lipid synthesis, which piles on more liver fat. Cycle 1 feeds itself.
Cycle 2: excess triglycerides overflow the saturated liver and start depositing elsewhere — including the pancreas. Fat accumulating around and inside the insulin-producing islets impairs beta cell function. Mechanisms include lipotoxicity (free fatty acids wrecking mitochondrial function in beta cells), endoplasmic reticulum stress from excessive proinsulin processing demands, and direct pro-inflammatory effects of the intrapancreatic fat itself.
Beta cell function degrades progressively as more fat accumulates in the pancreas.
Here’s where reversibility comes from, directly out of this mechanism: sufficiently reduce caloric intake and hepatic fat gets mobilized and cleared first — within days to weeks, liver fat drops dramatically, well before total body weight has moved much at all. As liver fat falls, hepatic insulin resistance improves and fasting glucose starts to normalize. Sustain the deficit, total body fat drops, pancreatic fat clears too — and beta cell function recovers.
First-phase insulin response — the fast initial secretion triggered by a glucose challenge, specifically lost early in type 2 diabetes — can return to normal or near-normal after enough pancreatic fat has cleared.
Taylor’s Newcastle studies, small proof-of-concept work first and then the larger DiRECT trial, produced direct MRI evidence: liver fat fell from abnormally elevated to normal within two weeks of starting the very low calorie diet used in DiRECT. Pancreatic fat cleared more slowly, over the full 12-month intervention.
Recovery of first-phase insulin response, measured by gold-standard intravenous glucose tolerance test, tracked directly with how much pancreatic fat had cleared — causal mechanistic evidence that the diabetes improvement came from restored beta cell function through fat removal, not simply eating less glucose.
THE DIRECT TRIAL: HOW THE EVIDENCE BASE WAS BUILT
DiRECT (Diabetes Remission Clinical Trial), published in The Lancet in 2018, was the pivotal study that pulled diabetes remission into mainstream clinical medicine. 306 participants with type 2 diabetes (duration 0-6 years), 49 primary care practices across Scotland and England.
The intervention group: all antidiabetic and antihypertensive medications withdrawn at enrollment, a total diet replacement (very low calorie formula, roughly 825-853 kcal/day), structured behavioral support for 12 months, then food reintroduction and long-term weight maintenance support.
At 12 months: 46% of the intervention group versus 4% of controls achieved remission. Mean weight loss in the intervention group, 10 kg. Remission tracked closely with weight loss — 86% of those who lost 15+ kg achieved remission; 57% of the 10-15 kg group; 34% of the 5-10 kg group.
Clean dose-response relationship, and mechanistically exactly what the Twin Cycle model predicts.
24-month follow-up: 36% of the intervention group still in remission — sustained reversal of a condition medicine had conventionally treated as permanent. The 5-year data (published 2024) found 13% still in remission at five years. Smaller share, sure. Still durable long-term reversal in a meaningful slice of participants.
The ones who held remission at five years had held onto most of their initial weight loss. The ones who regained weight mostly lost remission too — confirming the maintenance requirement, again.
The LOOK AHEAD trial wasn’t built to test remission specifically, but it enrolled over 5,000 adults with type 2 diabetes and randomized them to intensive lifestyle intervention versus standard care. The intensive group hit 8.6% weight loss at 1 year, 6% at 8 years. Partial or complete remission at 1 year: 11.5% of the intensive group versus 2% of controls. At 4 years: 7.3% versus 2%.
LOOK AHEAD used a less aggressive dietary intervention than DiRECT, which explains the lower rates. Depth of remission tracks with magnitude of weight loss. Every time.
THE ROLE OF BARIATRIC SURGERY: THE MOST POWERFUL REMISSION TOOL
The mechanisms split roughly two ways: partly weight loss-mediated (same fat-removal pathway as dietary intervention) and partly independent of weight loss entirely — dramatic glucose metabolism improvements show up within days of gastric bypass, well before meaningful weight loss, driven by hormones.
GLP-1 levels spike after gastric bypass (rerouting food past the duodenum ramps up the L-cell stimulus for GLP-1 secretion), bile acid profiles shift in ways that activate FXR and TGR5 receptors affecting glucose metabolism, and gut microbiome composition changes fast in ways that improve insulin sensitivity.
Current ADA guidelines recommend bariatric surgery for adults with type 2 diabetes and BMI ≥40 kg/m², and for BMI 35-39.9 with diabetes inadequately controlled despite lifestyle and optimal medical therapy. Emerging evidence and expert opinion increasingly support considering it at BMI 30-35 for people with type 2 diabetes who don’t achieve remission with lifestyle and medical therapy — particularly given increasingly favorable long-term metabolic and cardiovascular outcomes data from major bariatric cohorts.
The SELECT CHOICE trial and similar comparative studies found gastric bypass significantly outperformed both lifestyle intervention and pharmacotherapy for complete remission, with cardiovascular benefits of sustained remission extending over decades. For eligible candidates who haven’t responded adequately to lifestyle intervention, the surgery conversation belongs not as a last resort but as the most effective available treatment for the underlying condition.
GLP-1 RECEPTOR AGONISTS: THE PHARMACOLOGICAL PATHWAY TO REMISSION
The GLP-1 receptor agonist class — semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), liraglutide (Victoza/Saxenda) — is the biggest advance in diabetes pharmacology in decades. These drugs mimic endogenous GLP-1 (glucagon-like peptide-1, secreted by intestinal L-cells after eating), producing several complementary effects: enhanced glucose-dependent insulin secretion, suppressed glucagon secretion, slowed gastric emptying, reduced appetite, and at high doses, direct effects on hypothalamic appetite centers.
Semaglutide (a once-weekly injectable, escalated stepwise over the opening weeks of treatment) produces A1c reductions of 1.5-2% and weight loss of 5-10% in people with type 2 diabetes. Tirzepatide (weekly injectable, a dual GIP/GLP-1 receptor agonist) produces A1c reductions of 2-2.5% and weight loss of 15-20% in diabetes trials — closing in on bariatric surgery territory. The SURPASS trials found tirzepatide pushing A1c below 5.7% (normal range) in a substantial share of participants.
These medications can facilitate remission, particularly stacked with lifestyle intervention. The weight loss they produce activates the same Twin Cycle reversal mechanism as dietary caloric restriction. Several case series and pilot trials document remission rates of 30-50% with high-dose GLP-1 agonist therapy combined with structured dietary intervention in people with relatively short diabetes duration.
Worth flagging: achieving remission through GLP-1 medication likely requires staying on the medication to maintain it — unlike dietary or surgical remission, where the underlying structural changes (reduced fat depots) can hold through lifestyle alone once the acute intervention ends. The long-term data on stopping medication after GLP-1-induced remission is thin. Doesn’t diminish the value of medication-facilitated remission. It clarifies the commitment.
DIETARY APPROACHES TO REMISSION: LOW-CALORIE VS. LOW-CARBOHYDRATE
Two dietary strategies carry substantial evidence for facilitating remission:
Very Low Calorie Diet (VLCD) / Total Diet Replacement: This is the DiRECT approach — typically 600-850 kcal/day, entirely liquid formula (meal replacement shakes), removing food choices and decision fatigue for 8-12 weeks. The rationale: rapid liver fat clearance through sustained caloric deficit. Fat mobilizes out of the liver fast — detectable by MRI within weeks — producing quick improvements in fasting glucose before significant total weight loss even shows up.
The evidence for VLCD-induced remission is the most rigorous available (DiRECT was the first well-powered RCT). The problems are practical: demanding diet, needs real behavioral support to sustain for 12 weeks, hard to square with normal social eating. Supervised programs with medical monitoring are strongly preferred — VLCD carries risks of electrolyte disturbances, micronutrient deficiency, gallstone formation with rapid weight loss.
Antidiabetic medications and antihypertensives have to be reduced or stopped under medical supervision to prevent hypoglycemia and hypotension as glucose and blood pressure fall fast.
Low-Carbohydrate and Ketogenic Dietary Approaches: Carbohydrate restriction cuts postprandial glucose spikes directly and fast. Reduces insulin secretory demand, protecting beta cells from further exhaustion. Shifts the body toward fat oxidation, including mobilizing ectopic liver and pancreatic fat. And it produces real weight loss through reduced caloric intake — carbohydrate-restricted diets tend toward high satiety from more protein and fat, which cuts spontaneous caloric intake.
A meta-analysis of 6 months of low-carbohydrate versus control diet in type 2 diabetes found mean A1c reduction of 0.82% beyond control — comparable to adding a drug.
Individual case studies of full remission on sustained ketogenic diets have been published. The Virta Health study — non-randomized but large-scale, real-world — found a 60% reduction in diabetes medication use and 12% remission at one year among adults following a digitally-delivered ketogenic intervention.
The key difference: VLCD moves faster through more dramatic restriction. Low-carbohydrate may sustain better long-term for people who can’t stomach full meal replacement. Both work through overlapping mechanisms — reduced caloric intake, reduced hepatic and pancreatic fat, reduced insulin demand. Some clinicians run VLCD for initial rapid remission induction, then low-carbohydrate for maintenance. Borrowing speed from one, sustainability from the other.
EXERCISE AND BETA CELL RECOVERY
High-intensity interval training (HIIT) earns particular attention here because it produces superior insulin sensitivity gains per unit of time compared to moderate-intensity continuous exercise, and it specifically targets the mitochondrial dysfunction in skeletal muscle that drives insulin resistance. A meta-analysis in Diabetologia found HIIT reduced fasting glucose by 0.5 mmol/L more than moderate-intensity exercise in people with type 2 diabetes.
Proposed mechanisms: greater AMPK activation, greater mitochondrial biogenesis, larger increases in GLUT4 transporter expression with HIIT protocols.
Resistance training builds lean muscle mass, expanding the metabolic sink for glucose and producing lasting improvements in insulin sensitivity that outlast the immediate post-exercise window. Combined aerobic plus resistance training consistently beats either alone on glycemic outcomes. The DARE (Diabetes Aerobic and Resistance Exercise) trial found combined training reduced A1c by 0.97% versus 0.51% for aerobic alone and 0.38% for resistance alone — a real incremental benefit from combining modalities.
MAINTAINING REMISSION: THE LONG-TERM STRATEGY
Achieving remission is the first challenge. Maintaining it over years is the second, and arguably harder. The DiRECT 5-year data shows remission durability tracks directly with weight loss maintenance — which in turn requires sustained behavioral change without the intensive support structure the trial provided.
The foundational elements of sustained remission: persistent avoidance of the dietary patterns that drove the disease in the first place (high refined carbohydrates, sugar-sweetened beverages, caloric intake outpacing expenditure). Regular physical activity maintained across years, not months. Monitoring A1c and fasting glucose at regular intervals to catch early signs of recurrence — drift caught early allows course correction before full relapse.
Continued behavioral and social support matters too — people who stay in contact with health coaches, peer support programs, or digital monitoring tools show substantially better remission durability than those who exit structured support once they’ve had initial success.
The psychological framing matters as well. People who think of their remission as “cured” rather than “in remission” carry higher risk of behavioral drift — the former framing suggests the problem is gone and vigilance is no longer needed. The latter is accurate: the underlying metabolic vulnerability, the same genetic and biological factors that let diabetes develop in the first place, persists through remission. Sustained vigilance isn’t neurotic over-monitoring.
It’s appropriate recognition of a condition that needs active maintenance to stay quiet.
Common Questions About Defining Remission Reversal
Q: My doctor says type 2 diabetes is a progressive chronic disease that can only be managed. Is this accurate?
A: That was the consensus a decade ago, and it’s still the framing for a significant share of practicing clinicians. It’s no longer accurate as the only framing. The 2021 international consensus statement from the ADA, Endocrine Society, EASD, and Diabetes UK explicitly recognizes remission as a legitimate, achievable clinical goal for appropriate candidates.
The evidence from DiRECT, LOOK AHEAD, bariatric surgery studies, and GLP-1 agonist trials is clear: reversal to below-diabetic glucose levels without medication is achievable in a meaningful proportion of people with type 2 diabetes. If a doctor is unaware of this evidence or dismisses it, a second opinion from a physician current with the literature is a reasonable move.
Q: Can I achieve remission even if I’ve had diabetes for more than 10 years?
A: Remission gets less likely with longer duration, mainly because extended disease duration implies more cumulative beta cell damage from glucotoxicity, lipotoxicity, and apoptosis. Still — cases of remission at 10-15 year duration have been documented, and DiRECT included participants up to 6 years duration with meaningful outcomes. The key predictor isn’t duration itself but residual beta cell function, assessed by C-peptide levels (a marker of endogenous insulin secretion).
People with detectable C-peptide, even low levels, have residual beta cell function that can potentially recover. Very low or absent C-peptide indicates near-complete beta cell loss, which rules out remission.
Q: How much weight do I need to lose to achieve remission?
A: DiRECT data shows the clearest dose-response: roughly 86% remission with 15+ kg loss, 57% with 10-15 kg loss, 34% with 5-10 kg loss. Individual variation is large — some achieve remission with less weight loss, others need more.
Because the mechanism runs through liver and pancreatic fat clearance, the quality of the weight loss matters: visceral fat loss is worth more than subcutaneous fat loss, which is why dietary patterns specifically targeting visceral fat (low-carbohydrate, Mediterranean) may produce higher remission rates than the raw weight-loss number alone would predict.
Q: What happens to my diabetes medications during remission attempts?
A: Medication adjustment during remission attempts must happen under medical supervision. When dietary restriction or intensive exercise dramatically improves insulin sensitivity, glucose-lowering medications — particularly sulfonylureas and insulin — can cause dangerous hypoglycemia if doses aren’t reduced or stopped. SGLT2 inhibitors combined with very low carbohydrate diets raise the risk of euglycemic diabetic ketoacidosis (DKA), a serious complication. Blood pressure medications may need reduction as blood pressure falls with weight loss.
The entire medication regimen needs medical supervision and adjustment as metabolic parameters improve. Not something to manage independently. DiRECT stopped all antidiabetic medications at enrollment — with intensive monitoring replacing them. That approach requires clinical partnership.
Q: Is type 2 diabetes remission the same as type 1 diabetes remission?
A: No. Different diseases. Type 1 diabetes is autoimmune — the immune system has destroyed the insulin-producing beta cells. No functional beta cell reserve left to recover, so none of the remission mechanisms described here apply. Type 1 management is insulin replacement compensating for absent endogenous production; this can’t be reversed through lifestyle or weight loss.
Type 1 does have a “honeymoon phase” right after diagnosis, where residual beta cells temporarily provide some endogenous insulin — but that’s a temporary phenomenon during early autoimmune destruction, not a reversible metabolic state comparable to type 2 remission.
THE ROLE OF CONTINUOUS GLUCOSE MONITORING IN DIABETES REMISSION
Key CGM metrics beyond A1c: Time in Range (TIR) — percentage of time glucose sits between 70-180 mg/dL (target above 70% for people with diabetes, above 85% for remission-level control). Glucose variability (coefficient of variation) — higher variability tracks with increased oxidative stress and endothelial damage independent of average glucose.
Postprandial glucose peaks — the spike 1-2 hours after meals — predict cardiovascular risk better than fasting glucose in several studies, and reducing them is an early marker of dietary intervention success.
CGM data feeds the personalized nutrition approach to diabetes management. Research from the Weizmann Institute (Zmora et al., 2019) found glycemic response to identical foods varies dramatically between individuals — one person’s “healthy” whole grain toast produces a dramatic glucose spike while another person’s identical serving barely registers. Drivers of this individual variability include gut microbiome composition, body composition, baseline insulin sensitivity, and genetic factors.
CGM makes this individual variability visible and actionable — it lets each person pursuing remission identify their specific “trouble foods,” the ones spiking their glucose above target, and swap in alternatives that maintain TIR without requiring impossible willpower.
Tom started a structured program: a very low calorie diet for 12 weeks (under medical supervision, medication managed alongside it), followed by a Mediterranean-style low-carbohydrate maintenance diet and a daily 30-minute walking routine. At three months, A1c 6.1%. At six months, 5.8%. Off all three diabetes medications. Down 22 pounds.
His doctor, who’d been cautious about the remission claim at first, sent him a note acknowledging the evidence had been right and the clinical convention had been wrong. Tom put it simply: “I found out there was actually a door, and I walked through it.” That door is available to a lot more people than currently know it exists. Nobody’s been telling them where to find it — or even that they should be looking.
PSYCHOLOGICAL AND BEHAVIORAL DIMENSIONS OF DIABETES REVERSAL
The clinical evidence for diabetes reversal is clear. The behavioral execution is where most people succeed or fail. Understanding the psychological dimensions of sustained dietary and lifestyle change isn’t a soft addition to the evidence base — it’s central to actually getting the outcomes the trials show are possible.
DiRECT wasn’t merely a dietary intervention. It was a behavioral intervention with diet as the tool. The structured 16-session curriculum covered goal-setting, problem-solving, relapse prevention, social support activation, cognitive strategies for managing food environments. Sustained contact with health coaches throughout the 12-month intervention mattered at least as much as the dietary prescription itself.
Habit formation research suggests behavioral changes become self-sustaining once they turn automatic rather than effortful — once the new behavior takes less willpower than the old one. Roughly 66 days for a new behavior to become automatic, per Phillippa Lally’s research at University College London, which means the first two months of any remission attempt are the highest-resistance phase.
Simplifying environmental design — removing high-glycemic foods from the home, establishing automatic post-meal walking habits, keeping low-glycemic foods prepared and accessible — reduces the activation energy each individual behavioral decision requires and shifts the default toward remission-supportive choices.
Social context is one of the strongest determinants of long-term dietary and lifestyle success. Partners and family who share or support the dietary changes dramatically improve outcomes; social environments that keep presenting high-glycemic eating without alternatives undermine even well-motivated people. Which is why family engagement, peer support groups (in-person and digital both), and home food environment modification are consistently flagged as high-value components of long-term remission maintenance programs.
Nobody sustains behavior change in an unsupportive environment on willpower alone. Environment wins eventually. Designing the environment before willpower runs out is the strategic move that separates sustained remission from the initial success most people can achieve but fewer can hold onto.
EMERGING APPROACHES: WHAT’S COMING IN DIABETES REVERSAL
The field of type 2 diabetes remission is moving fast. Several emerging approaches will likely expand the toolkit in the coming years.
Tirzepatide (Mounjaro), a dual GIP/GLP-1 receptor agonist, produces the largest pharmacological weight loss and A1c reduction of any currently approved type 2 diabetes medication. The SURMOUNT-2 trial found tirzepatide 15mg produced 15.7% body weight reduction and A1c reduction of 2.4% in adults with type 2 diabetes and obesity — closing in on bariatric surgery outcomes.
As the evidence base for tirzepatide-facilitated remission matures, it’s likely to become a standard component of remission protocols for appropriate candidates — particularly those for whom bariatric surgery is inappropriate or declined.
Precision medicine approaches to remission are developing too. The recognition that type 2 diabetes isn’t a single disease but a cluster of distinct subtypes — different driving mechanisms (beta cell failure predominant vs. insulin resistance predominant vs. lipid-mediated vs. others) — is starting to inform personalized remission strategies. The ANDIS cohort in Sweden identified five distinct diabetes subtypes with different complication rates and different responses to identical treatments.
People with the “severe insulin-deficient” subtype have poor beta cell function at diagnosis and are unlikely to achieve remission through weight loss alone; people with the “mild obesity-related” subtype are the best candidates for lifestyle-based remission. Typing individuals before recommending an approach would let strategy get matched to biology — a refinement of the current one-size-fits-all, or maybe one-size-fits-many, approach.
Microbiome-based interventions remain experimental but represent a genuinely interesting frontier. Fecal microbiome transplantation (FMT) from lean, insulin-sensitive donors to people with type 2 diabetes produces temporary insulin sensitivity improvements in small trials — the effect is real but not yet durable without concurrent dietary change.
Combining microbiome optimization (high-fiber diet, fermented foods, possibly targeted probiotic or FMT interventions) with dietary and exercise remission protocols is an active area of investigation that may push outcomes beyond what either approach achieves alone.
The economic case for diabetes remission programs deserves plain acknowledgment. Lifetime healthcare costs for a person with type 2 diabetes run approximately $85,000 to $125,000 higher than a matched individual without diabetes. Complications — cardiovascular disease, kidney failure requiring dialysis, lower limb amputation, blindness — each carry six-figure treatment costs beyond that baseline. The DiRECT intervention cost approximately $1,200 per participant over 12 months.
A remission that persists ten years and prevents even one major complication pays for itself many hundreds of times over. The failure to scale diabetes remission programs isn’t a medical failure. It’s a healthcare system prioritization failure. The evidence is there. The cost-effectiveness is overwhelming.
The failure sits in the systems of reimbursement, training, and clinical culture that keep operationalizing diabetes as a chronic condition to manage rather than a metabolic state to reverse.
The conversation about diabetes reversal is ultimately a conversation about what gets accepted as permanent. For decades, medicine accepted that type 2 diabetes was irreversible. That acceptance wasn’t based on evidence — there was simply no evidence for the alternative yet, because nobody had run the systematic clinical trials to test it. The assumption got made, it became clinical culture, and clinical culture became individual prognosis.
Patients were told the diagnosis was permanent because their doctors had been taught it was permanent, because the system was structured around management rather than reversal. Then the trials got done. The mechanistic studies got done. The pancreatic fat got visualized by MRI. Beta cell function got measured before and after intervention. The data came back unambiguous. The disease that was “permanent” had structure. And structure, once understood, can be acted on.
Tom’s story is available to far more people with type 2 diabetes than currently know it. The limitation isn’t the biology. The biology cooperates. The limitation is the information gap between what the trials have established and what the average person with a recent diagnosis hears from their provider in a ten-minute appointment. Closing that gap is the whole point of this article.
The Practical Framework: Applying Defining Remission Reversal Actually In Real Life
References
Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map